You are here:Home-SARS-CoV-2 Related-SARS-CoV-2 Inhibitors-PF-07817883
PF-07817883

Chemical Structure : PF-07817883

CAS No.: 2755812-39-4

PF-07817883 (Ibuzatrelvir, PF07817883)

Catalog No.: PC-22258Not For Human Use, Lab Use Only.

PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (Mpro) with Ki value of 2.48 nM, EC50 of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).

Packing Price Stock Quantity
1 mg $188 In stock
5 mg $458 In stock
10 mg $758 In stock
25 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (Mpro) with Ki value of 2.48 nM, EC50 of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).
PF-07817883 (Ibuzatrelvir) shows improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid.
PF-07817883 (Ibuzatrelvir) inhibits the SARS-CoV-1 Mpro (IC50 = 18 nM) and MERS Mpro (IC50 = 930 nM) activity, respectively, but has a much smaller disparity in the cell-based antiviral assays (SARS-CoV-1 EC50 = 157 nM and MERS EC50 = 158 nM).
PF-07817883 (Ibuzatrelvir) potently inhibits SARS-CoV-2 viral replication with EC50 and EC90 values of 34 nM and 70 nM respectively in Vero76 cells.
PF-07817883 (Ibuzatrelvir) also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir.

Physicochemical Properties

M.Wt 489.50
Formula C21H30F3N5O5
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

methyl ((S)-1-((2S,4R)-2-(((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)carbamoyl)-4-(trifluoromethyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate

References

1. Allerton CMN, et al. J Med Chem. 2024 Apr 30. doi: 10.1021/acs.jmedchem.3c02469.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: